166 related articles for article (PubMed ID: 38536616)
1. Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study.
Li Y; Lv C; Dang L; Lin B; Tao J; Zhang C; Zhou X; Ma H; Lu Y; Chen R; Li J; Dou G; Liang Y; Liang Y; Shi Y
Dermatol Ther (Heidelb); 2024 Apr; 14(4):907-918. PubMed ID: 38536616
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study.
Ying L; Suyun J; Yanhua L; Yunsheng L; Li D; Lin D; Chengzhi L; Bingjiang L; Furen Z; Wendi S; Jinnan L; Yu D; Guanshen D; Shi Y
Adv Ther; 2023 Dec; 40(12):5464-5474. PubMed ID: 37824031
[TBL] [Abstract][Full Text] [Related]
3. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
4. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
[TBL] [Abstract][Full Text] [Related]
5. The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study.
Li Y; Dang L; Lv C; Lin B; Tao J; Yu N; Deng Y; Wang H; Kang X; Qin H; Chen R; Li J; Liang Y; Liang Y; Shi Y
Drug Saf; 2024 Jul; 47(7):711-719. PubMed ID: 38689136
[TBL] [Abstract][Full Text] [Related]
6. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
9. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
Egeberg A; Hawkes JE; Somani N; Burge R; See K; Gallo G; McKean-Matthews M; Gooderham M; Han G; Armstrong A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):1007-1018. PubMed ID: 38647975
[TBL] [Abstract][Full Text] [Related]
10. Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis.
Hebert AA; Bobonich MA; Rodriguez Capriles C; Gallo G; Li L; Somani N; Ridenour T; Wang Y; Edson-Heredia E; Becker EM
Pediatr Dermatol; 2022 Jan; 39(1):55-60. PubMed ID: 34931346
[TBL] [Abstract][Full Text] [Related]
11. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Valenti M; Gargiulo L; Ibba L; Malagoli P; Amoruso F; Balato A; Bardazzi F; Burlando M; Carrera CG; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Maurelli M; Megna M; Orsini D; Travaglini M; Costanzo A; Narcisi A
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1649-1657. PubMed ID: 38748344
[TBL] [Abstract][Full Text] [Related]
14. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
[TBL] [Abstract][Full Text] [Related]
16. Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Gooderham M; Vender R; Crowley J; Hong HC; Feely M; Garrelts A; See K; Konicek B; Green L
Dermatol Ther (Heidelb); 2024 Feb; 14(2):441-451. PubMed ID: 38332436
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
Leonardi C; Reich K; Foley P; Torii H; Gerdes S; Guenther L; Gooderham M; Ferris LK; Griffiths CEM; ElMaraghy H; Crane H; Patel H; Burge R; Gallo G; Shrom D; Leung A; Lin CY; Papp K
Dermatol Ther (Heidelb); 2020 Jun; 10(3):431-447. PubMed ID: 32200512
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).
Piaserico S; Riedl E; Pavlovsky L; Vender RB; Mert C; Tangsirisap N; Haustrup N; Gallo G; Schuster C; Brunner PM
Front Med (Lausanne); 2023; 10():1185523. PubMed ID: 37457564
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Mrowietz U; Barker J; Conrad C; Jullien D; Gisondi P; Flower A; Reddy J; Paris M; Picard H; Jardon S; Augustin M
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):348-355. PubMed ID: 36300769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
